Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce an expansion of the manufacturing with AstraZeneca to include pharmaceutical manufacturing.    

This agreement expands the scope of Aji Bio-Pharma's service offerings to AstraZeneca to include aseptic filling finishing services at its San Diego, California facility , in addition to the small molecule manufacturing services being carried out at Belgium.

"We are delighted to expand our manufacturing agreement with AstraZeneca and support them with additional service offerings," said Magnus Busch , global account manager for Ajinomoto Bio-Pharma Services. " Our team San Diego is proud to join our Belgian colleagues in support of AstraZeneca. This expanded agreement builds on our commitment to be a leading, reliable and innovative partner for our customers."

About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract manufacturing and development organization with sites in Belgium, the United States, Japan and India , providing comprehensive development, cGMP manufacturing and aseptic fill finishing services for API and intermediates of small and large molecules. Ajinomoto Bio-Pharma Services offers a wide range of innovative platforms and capabilities for preclinical and pilot programs at commercial quantities, including Corynex® protein expression technology, oligonucleotide synthesis, Antibody Drug Conjugations (ADC), APIs ofhigh potency (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet the needs of our customers. More information at: www.AjiBio-Pharma.com

Source: prnewswire.com